A Nature Communications study reported that plasma biomarkers—eMTBR-tau243 and p-tau205—can stage Alzheimer’s disease and predict cognitive decline comparably to PET imaging for later tau aggregation stages. The work centered on measurable rises in both biomarkers during progression to the tau-aggregation phase. The report positions a blood-based approach for staging and risk stratification, which could expand access beyond PET imaging and support trial enrichment strategies. It also underscores the need to understand performance across disease stages and patient populations as home- and decentralized testing moves forward. For biotech and diagnostics stakeholders, the key take-away is the clinical utility angle: biomarker dynamics can be used not only to detect disease but to place patients within a progression framework.